Advertisement
Advertisement
U.S. Markets open in 3 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3900+0.0300 (+8.33%)
At close: 04:00PM EDT
0.4100 +0.02 (+5.13%)
Pre-Market: 05:06AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3600
Open0.3500
Bid0.0000 x 900
Ask0.0000 x 900
Day's Range0.3500 - 0.4215
52 Week Range0.3010 - 3.7500
Volume1,011,552
Avg. Volume952,416
Market Cap42.472M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.3560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est699.23
  • Benzinga

    Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

    Mereo BioPharma Group plc (NASDAQ: MREO) has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat (MPH-966) in severe alpha-1 antitrypsin deficiency-(AATD) associated emphysema. Emphysema is a lung disease caused by damage to the small air sacs in the lungs (alveoli). The study evaluated two different doses of alvelestat (high or low dose) or placebo over 12 weeks on three primary biomarker endpoints associated with AATD-related lung disease (AATD-LD), blood ne

  • GlobeNewswire

    Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

    Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease No safety signals were associated with alvelestat Conference Call Today at 10:30 a.m. ET LONDON and REDWOOD CITY, Calif., May 09, 2022

  • GlobeNewswire

    Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

    Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ETLONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema. Confe

Advertisement
Advertisement